(MENAFN- iCrowdNewsWire)

Molecular Pharming Market Size is valued at USD 1655.3 Mn in 2023 and is predicted to reach USD 3516.73 Mn by the year 2034 at a 8.1% CAGR during the forecast period for 2025-2034 .

Latest Drivers Restraint and Opportunities Market Snapshot:

Key factors influencing the global Molecular Pharming market are:

• Rising Research in Bio-Farming
• Growing Demand for Cost-Effective, Scalable, And Fast Methods Of Producing Vaccines And Therapeutic Proteins
• Advantages Over traditional Methods of Protein Production

The following are the primary obstacles to the Molecular Pharming market's expansion:

• High Costs of Development and Scale-Up
• Risks of Contamination
• High Initial Investment Costs hamper Target Market Expansion

Get Free Access to Demo Report, Excel Pivot and ToC:

Future expansion opportunities for the global Molecular Pharming market include:

• Rising Demand for Biologics
• Rising Prevalence of Disease Indications
• Expansion into Nutraceuticals to Fuel Focused Market Growth Opportunity

Key Industry Insights & Findings from the report:

• North America is expected to have the largest market share in 2024 due to its sophisticated biopharmaceutical industry, significant R&D expenditures, and robust healthcare system, which allow for the regional commercialization of molecular pharmaceutics.
• Maize, a grain used to create recombinant proteins such as antibodies, hormones, and vaccines, is expected to dominate the market in the next years.
• Asia Pacific is expected to expand at the fastest rate due to significant success in applying modern agriculture methods.
• The rising prevalence of chronic illnesses and the need for new therapies are boosting demand for biopharmaceuticals, which molecular pharming can effectively create.

Market Analysis:

Molecular pharming, or molecular farming, is a cutting-edge biotechnology approach that leverages genetically engineered plants or animals for the production of pharmaceutical compounds. This methodology utilizes the inherent biological processes of living organisms to synthesize complex therapeutic molecules.

Compared to conventional manufacturing methods, molecular pharming provides notable advantages in cost efficiency and scalability. Through the application of genetic engineering, specific genes can be introduced into plants or animals, facilitating the precise and consistent production of therapeutic proteins, biopharmaceuticals, and vaccines.

List of Prominent Players in the Molecular Pharming Market:

• Leaf Expression Systems
• ORF Genetics hf.
• Agrenvec S.L.
• PlantForm
• Protalix Biotherapeutics
• Kbio, Inc.
• Cape Biologix Technologies (Cape Bio Pharm
• Bright Biotech
• Moolec Science SA
• Miruku
• Tiamat Sciences Corp.
• IngredientWerks
• Core Biogenesis
• Diamante Società Benefit S.r.l.
• Elo Life Systems

Expert Knowledge, Just a Click Away:

Recent Developments:

• In April 2024, Nobell Foods, a molecular farming firm that makes animal-free cheese with soy-derived casein proteins, rebranded as Alpine Bio and received a new dairy protein patent. The San Francisco-based firm will now function as a subsidiary under the new name, Alpine Bio, and its scope has been broadened to include 15 proteins that may be produced in diverse plants using molecular farming.
• In October 2023, Moolec Science, which specializes in plant-based animal protein manufacturing via molecular pharming, raised $30 million from investors using convertible notes. The money will help the firm focus on expanding its research and development activities in more meat compounds and proteins. Moolec Science intends to include meat proteins into the matrix of soy and pea proteins, as opposed to standard ways of extracting and purifying animal proteins from their sources.
• In September 2023, Bio Better, a Food Technology business, opened its first food-grade pilot plant in northern Israel to speed up the production of growth factors for meat production. Using tobacco plants as self-sustaining bioreactors, the business aims to produce 100kg per day and hopes to increase to 5 tons by 2025, lowering industry costs.

Molecular Pharming Market Dynamics

Market Drivers: Growing Investment in Bio-Pharming Research

The molecular pharming market is being significantly driven by rising investments in bio-pharming research within the pharmaceutical and biotechnology sectors. This approach, which utilizes genetically engineered plants or animals to produce therapeutic proteins, vaccines, and other biopharmaceuticals, is benefiting from advancements in gene-editing technologies, particularly CRISPR/Cas9.

These innovations enable precise modifications of host organisms, improving product yield, quality, and overall manufacturing efficiency while reducing production costs. Moreover, researchers are expanding the range of host organisms to include alternatives such as algae, fungi, and insects, thereby diversifying molecular production platforms.

Market Challenges: High Development and Scale-Up Costs

Despite its promising potential, the molecular pharming market faces challenges related to the substantial costs associated with early-stage development and industrial-scale production. While the technology offers scalability, operational flexibility, and long-term cost advantages, the significant initial investment required for research, development, and commercial deployment may restrict adoption, particularly among emerging market players and small to mid-sized biopharmaceutical companies.

Regional Outlook: North America to Lead Market Growth

North America is anticipated to lead the global molecular pharming market, achieving the highest compound annual growth rate (CAGR) during the forecast period. This growth is supported by the region's mature biopharmaceutical ecosystem, characterized by robust R&D initiatives and technological innovation. The presence of prominent industry players and leading research institutions further strengthens market expansion.

Additionally, the increasing prevalence of chronic diseases and growing demand for cost-effective therapeutic solutions are driving molecular pharming adoption. Well-established supply chains, extensive distribution networks, and supportive healthcare expenditure and reimbursement policies enable timely access to molecular pharming products, reinforcing long-term market growth in the region.

Unlock Your GTM Strategy:

Segmentation of Molecular Pharming Market-

By Technology-

• Gene Gun
• Agro infiltration
• Electroporation
• Agrobacterium-Mediated Gene Transfer
• Others

By Application-

• Recombinant Antibodies
• Hormones
• Vaccines
• Industrial Enzymes
• Proteins & Protein-Based Materials
• Technical Reagents
• Nutritional Products
• Others

By Crop Source

• Maize
• Barley
• Tobacco
• Safflower
• Rice
• Alfalfa

By End-User

• Biotechnology & Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Tags: Molecular Pharming Market See Campaign:
Contact Information:

Contact us: InsightAce Analytic Pvt. Ltd. Visit: Tel : +1 607 400-7072 Asia: +91 79 72967118 ...

Tags:
CE , Go Media , Go Media2 , iCN Internal Distribution , Reportedtimes , Research Newswire , English

MENAFN06102025003318003403ID1110158644